Big Bull
2021-11-22
👍
Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
5
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":872777574,"tweetId":"872777574","gmtCreate":1637582901485,"gmtModify":1637582901485,"author":{"id":4094912318336650,"idStr":"4094912318336650","authorId":4094912318336650,"authorIdStr":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":12,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>👍 </p></body></html>","htmlText":"<html><head></head><body><p>👍 </p></body></html>","text":"👍","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/872777574","repostId":1171692239,"repostType":4,"repost":{"id":"1171692239","kind":"news","pubTimestamp":1637582731,"share":"https://www.laohunote.com/m/news/1171692239?lang=zh_CN&edition=full","pubTime":"2021-11-22 20:05","market":"us","language":"en","title":"Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1171692239","media":"Reuters","summary":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its ","content":"<p>BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.</p><p><blockquote>路透北京 11 月 22 日 - 中国科技巨头百度 (9888.HK) 周一表示，已将其信使 RNA (mRNA) 序列算法授权给赛诺菲公司，用于设计疫苗和治疗产品，这是其与全球主要制药商达成的首个此类商业协议。</blockquote></p><p> Sanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more</p><p><blockquote>赛诺菲 (SASY.PA) 在大流行之前是世界上最大的疫苗制造商之一，但这家法国公司在开发针对 COVID-19 的 mRNA 疫苗方面被竞争对手 BioNTech /辉瑞 (PFE.N) 和 Moderna (MRNA.O) 击败。阅读更多</blockquote></p><p> Sanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.</p><p><blockquote>赛诺菲于 9 月份停止了自己的 mRNA COVID-19 疫苗试验，转而专注于与葛兰素史克 (GSK.L) 合作，将另一种基于更传统的蛋白质方法的 COVID-19 候选疫苗推向市场。</blockquote></p><p> The French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.</p><p><blockquote>法国集团Saidit将把其mRNA资源集中在其他有强烈未满足需求的传染病和治疗药物上。</blockquote></p><p> Baidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.</p><p><blockquote>领导该项目的百度科学家黄亮表示，当赛诺菲使用其算法发现的任何基于mRNA的疗法或候选疫苗进入临床试验时，百度将获得里程碑式的付款。</blockquote></p><p> \"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.</p><p><blockquote>黄告诉路透社：“该协议包括里程碑付款的事实表明，[赛诺菲]对将采用百度算法开发的候选药物纳入临床试验并推向市场充满信心。”他拒绝透露交易规模。</blockquote></p><p> An mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.</p><p><blockquote>基于mRNA的疫苗含有mRNA序列，该序列指示人体细胞产生可以刺激免疫系统采取行动的蛋白质。</blockquote></p><p> Baidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.</p><p><blockquote>黄说，百度的算法旨在提供更多优化的mRNA序列，有早期迹象表明，它可能比标准算法更适合疫苗和治疗药物开发。</blockquote></p><p> Specifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to lab studies and animal tests, which haven't gone through peer-review.</p><p><blockquote>具体到新冠肺炎候选疫苗，根据实验室研究和动物测试，那些含有百度算法生成的mRNA序列的疫苗更稳定，并且似乎需要比基于标准算法的基线注射更小的剂量，这些疫苗尚未经过同行评审。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development<blockquote>百度与赛诺菲合作，将其算法用于mRNA疫苗和疗法开发</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-22 20:05</span>\n</p>\n</h4>\n</header>\n<article>\n<p>BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.</p><p><blockquote>路透北京 11 月 22 日 - 中国科技巨头百度 (9888.HK) 周一表示，已将其信使 RNA (mRNA) 序列算法授权给赛诺菲公司，用于设计疫苗和治疗产品，这是其与全球主要制药商达成的首个此类商业协议。</blockquote></p><p> Sanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more</p><p><blockquote>赛诺菲 (SASY.PA) 在大流行之前是世界上最大的疫苗制造商之一，但这家法国公司在开发针对 COVID-19 的 mRNA 疫苗方面被竞争对手 BioNTech /辉瑞 (PFE.N) 和 Moderna (MRNA.O) 击败。阅读更多</blockquote></p><p> Sanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.</p><p><blockquote>赛诺菲于 9 月份停止了自己的 mRNA COVID-19 疫苗试验，转而专注于与葛兰素史克 (GSK.L) 合作，将另一种基于更传统的蛋白质方法的 COVID-19 候选疫苗推向市场。</blockquote></p><p> The French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.</p><p><blockquote>法国集团Saidit将把其mRNA资源集中在其他有强烈未满足需求的传染病和治疗药物上。</blockquote></p><p> Baidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.</p><p><blockquote>领导该项目的百度科学家黄亮表示，当赛诺菲使用其算法发现的任何基于mRNA的疗法或候选疫苗进入临床试验时，百度将获得里程碑式的付款。</blockquote></p><p> \"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.</p><p><blockquote>黄告诉路透社：“该协议包括里程碑付款的事实表明，[赛诺菲]对将采用百度算法开发的候选药物纳入临床试验并推向市场充满信心。”他拒绝透露交易规模。</blockquote></p><p> An mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.</p><p><blockquote>基于mRNA的疫苗含有mRNA序列，该序列指示人体细胞产生可以刺激免疫系统采取行动的蛋白质。</blockquote></p><p> Baidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.</p><p><blockquote>黄说，百度的算法旨在提供更多优化的mRNA序列，有早期迹象表明，它可能比标准算法更适合疫苗和治疗药物开发。</blockquote></p><p> Specifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to lab studies and animal tests, which haven't gone through peer-review.</p><p><blockquote>具体到新冠肺炎候选疫苗，根据实验室研究和动物测试，那些含有百度算法生成的mRNA序列的疫苗更稳定，并且似乎需要比基于标准算法的基线注射更小的剂量，这些疫苗尚未经过同行评审。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/markets/europe/baidu-partnership-with-sanofi-use-its-algorithm-mrna-vaccine-therapy-development-2021-11-22/\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNYNF":"Sanofi","BIDU":"百度","09888":"百度集团-SW"},"source_url":"https://www.reuters.com/markets/europe/baidu-partnership-with-sanofi-use-its-algorithm-mrna-vaccine-therapy-development-2021-11-22/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171692239","content_text":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.\nSanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more\nSanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.\nThe French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.\nBaidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.\n\"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.\nAn mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.\nBaidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.\nSpecifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to lab studies and animal tests, which haven't gone through peer-review.","news_type":1,"symbols_score_info":{"SNYNF":0.9,"BIDU":0.9,"09888":0.9}},"isVote":1,"tweetType":1,"viewCount":10129,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/872777574"}
精彩评论